目的采用化疗药物泰索帝单周和三周方案二线治疗老年晚期非小细胞肺癌,对比观察两组病人的临床疗效和毒副作用。

方法经组织学或细胞学确诊的晚期非小细胞肺癌患者82例,随机分为两组,A组:泰索帝75mg/m2IVD1,每3周重复。B组:泰索帝30mg/m2IVD1,D8,D15,每4周重复。化疗3个周期后评价疗效和毒副反应。结果A组有效率(RR)23.1%,B组有效率(RR)16.3%,两组有效率评价无显著性差异(P>0.05)。A组毒副反应明显高于B组,主要为中性粒细胞下降(P<0.005)及粒细胞减少性发热(P<0.01)。结论使用泰索帝每周方案作为老年非小细胞肺癌的二线化疗方案,与标准的三周方案相比,毒副反应降低,而临床疗效没有下降。
Objective To observation the efficacy and toxicity using different dosage of weekly and three-week taxotere as second-line chemotherapy for Elderly NSCLC.Methods 82 patients were randomized to receive either taxotere 75 mg/m2 every 3 weeks(arm A)or taxotere 30 mg/m2 weekly for 3 weeksrepeatedevery4weeks.Treatment reaction and toxicity were evaluated after three cycles of chemotherapy.Results The reaction rate(RR)was 23.1% and 16.3% respectively in the two arms.There was no any significant difference between them(P>0.05).However,there was a significantly higher toxicity,mainly neutropenia and febrile neutropenia in arm A than that in arm B.Conclusion For elderly patients with advanced NSCLC,second-line chemotherapy with weekly taxotere may have a comparable efficacy and better toxcity profile,compared with every-3-week dosing regime.
【Keyword】：Elderly non-small cell lung cancer;Taxotere;Chemotherapy
老年晚期肺癌患者机体储备适应力和抵抗力均明显下降,各组织器官发生不同的退行病变和器质病变,骨髓储备功能减少,经一线治疗后其耐受性更差,因此研究探讨一种更合适的治疗老年非小细胞肺癌的二线化疗方案,解决老年非小细胞肺癌因难以耐受毒副反应而放弃二线化疗的难题非常必要